U.S. Markets open in 7 hrs 42 mins

GlaxoSmithKline plc (GSK)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
40.18+0.26 (+0.65%)
At close: 4:02PM EDT
People also watch
Full screen
Previous Close39.92
Bid0.00 x 0
Ask0.00 x 0
Day's Range39.86 - 40.19
52 Week Range37.20 - 44.54
Avg. Volume2,712,184
Market Cap91.8B
PE Ratio (TTM)39.94
Earnings DateN/A
Dividend & Yield1.99 (4.97%)
Ex-Dividend Date2017-08-09
1y Target EstN/A
Trade prices are not sourced from all markets
  • Is GlaxoSmithKline plc (GSK) a Suitable Value Stock?
    Zacks16 hours ago

    Is GlaxoSmithKline plc (GSK) a Suitable Value Stock?

    GlaxoSmithKline is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.

  • Reuters23 hours ago

    GSK's new triple lung drug beats other modern inhalers in study

    GlaxoSmithKline produced clinical data on Wednesday showing its newly approved three-in-one inhaler reduced life-threatening attacks in chronic obstructive pulmonary disease (COPD) patients more than other modern treatments. Britain's biggest drugmaker believes the results confirm the potential of the once-daily single inhaler, Trelegy Ellipta, a product it hopes will offset the impact of generic competition to the older lung drug Advair. Trelegy won approval based on clinical tests showing it improved lung function and exacerbations more than AstraZeneca's long-established two-drug inhaler Symbicort, which works in a similar way to Advair.

  • FDA OKs Glaxo's inhaler, first one to combine 3 medicines
    Associated Pressyesterday

    FDA OKs Glaxo's inhaler, first one to combine 3 medicines

    TRENTON, N.J. (AP) — The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis.